Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality?

Emanuela Dell'AquilaTea ZeppolaMarco StellatoFrancesco PantanoMario ScartozziCristina MadaudoFilippo PietrantonioChiara CremoliniGiuseppe AprileBruno VincenziRoberto MorettoMarco PuzzoniSilvio Ken GarattiniRiccardo LobefaroGiuseppe ToniniDaniele Santini

Published in: Clinical Medicine Insights. Oncology (2020)

In this retrospective analysis, anti-EGFR inhibitors showed to be a suitable addendum to chemotherapy in the I and II line, with an excellent tolerance and safety profile both in I and II line.

Keyphrases

small cell lung cancer
small bowel
epidermal growth factor receptor
squamous cell carcinoma
tyrosine kinase
locally advanced
rectal cancer